Close Menu

NEW YORK – With the recent launch of Target-NG, an assay to determine antimicrobial susceptibility of gonorrhea infections, San Jose, California-based startup Shield Bio appears to be the first commercial clinical laboratory in the US to offer a nanopore sequencing-based assay for routine diagnostic testing.

Shield is also developing its technology for other applications — including hospital-acquired infection and sepsis testing — relying on the advantages that sequencing has for detecting a large number of evolving resistance mechanisms as compared to PCR-based tests.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.